| ¿µ¹® | heart disease | ÇÑ±Û | ½ÉÀ庴 |
|---|---|---|---|
| ¼³¸í | ¼øÈ¯±â Áúȯ Áß ½ÉÀåÀÇ º´. ÀϹÝÀûÀ¸·Î ½ÉÀåÇ÷°üÀ̳ª ½ÉÀåÀÇ º´µµ Æ÷ÇԵȴÙ. º´ÅÍÀÇ ºÎÀ§¿¡ ÀÇÇÑ º´¸®ÇغÎÇÐÀû ºÐ·ù¿Í º´Àο¡ ÀÇÇÑ ºÐ·ù°¡ ÀÖ´Ù. ÀüÀÚ´Â ¼ö ½Ê ³â ÀüºÎÅÍ ¾²¿©Á® ¿ÔÀ¸³ª ±Ù³â¿¡ ¿Í¼ º»ÁúÀûÀÎ ¿øÀοä¹ýÀÌ °¡´ÉÇÏ°Ô µÈ ÀÌÈÄ´Â ÈÄÀÚÀÇ ºÐ·ù°¡ ÀÇÀǰ¡ ÀÖ¾î¼ ¸¹ÀÌ ¾²ÀÌ°Ô µÇ¾ú´Ù. º´ÅÍ ºÎÀ§·Î´Â ½É³»¸·(ÆÇ¸·)-½ÉÀå±Ù-½ÉÀ帷, ±× ¹ÛÀÇ °ÍÀ» µé ¼ö ÀÖÀ¸¸ç, °¢°¢ ½É³»¸·¿°-½ÉÀåÆÇ¸·Áõ-½É±Ù¿°-½É±Ù°æ»ö-½ÉÀ帷¿°-¼±Ãµ¼º ½ÉÀ庴(½ÉÀå±âÇü) µîÀÌÆ÷ÇԵȴÙ. º´Àκ°¿¡¼´Â ½ÉÀå±âÇüÀ» ºñ·ÔÇÏ¿© ·ù¸¶Ä¡½º ½ÉÀ庴-¸Åµ¶¼º ½ÉÀ庴-°íÇ÷¾Ð¼º ½ÉÀ庴-½ÉÀ嵿¸Æ°æÈ¼º ½ÉÀ庴-Æó¼º½ÉÀå-¼¼±Õ¼º ½É³»¸·¿°-½ÉÀå½Å°æÁõ µîÀ¸·Î ³ª´©¾îÁö¸ç, ºÎÁ¤¸ÆÀ̳ª ¹æ½ÇÂ÷´Ü µîÀÇ ÀÚ±ØÀüµµ°èÀÇ Àå¾Ö¿¡ ÀÇÇÑ °Íµµ Áõ¼¼ÀÇ Çϳª·Î º¼ ¼ö ÀÖ´Ù. ½ÉÀ庴Àº ÀÚ°¢ÀûÀ¸·Î´Â ¹«Áõ¼¼ÀÎ °Í¿¡¼ºÎÅÍ ½ÉÀå±â´É»ó½Ç·Î È£Èí°ï¶õ±îÁö ÀÖ´Ù. |
||
| ¿µ¹® | allergic disease | ÇÑ±Û | ¾Ë·¹¸£±âº´ |
|---|---|---|---|
| ¼³¸í | ³ÐÀº ¶æÀ¸·Î´Â IÇü, IIÇü, IIIÇü ¹× IVÇüÀÇ ¾Ë·¹¸£±â ¹ÝÀÀ¿¡ ÀÇÇØ¼ »ý±â´Â ¸ðµç º´À» °¡¸®Å²´Ù. ±×·¯³ª º¸Åë ¾Ë·¹¸£±âº´À̶ó°í Çϸé Á¼Àº ¶æÀ» °¡¸®Å°´Â °æ¿ì°¡ ¸¹°í, IÇüÀÇ ¾Ë·¹¸£±â¹ÝÀÀ¿¡ ÀÇÇØ¼ »ý±â´Â °ÍÀ» °¡¸®Å²´Ù. Áï ¾ÆÅäÇǺ´°ú ¸¶Âù°¡Áö ¶æÀ¸·Î ÇØ¼®µÇ´Â °æ¿ì°¡ ¸¹°í, ±â°üÁöõ½Ä, ¾Ë·¹¸£±âÄÚ¿°, ¾Ë·¹¸£±âÁ¡¸·¿°, µÎµå·¯±â, ¾Æ³ªÇʶô½Ã½º µîÀÌ ¿©±â¿¡ ¼ÓÇÑ´Ù. |
||
| ¿µ¹® | Alzheimer's disease | ÇÑ±Û | ¾ËÃ÷ÇÏÀ̸Ӻ´ |
|---|---|---|---|
| ¼³¸í | ÅðÇ༺ ³úº´. ³ëÀο¡¼ÀÇ Ä¡¸ÅÀÇ ¿øÀÎ Áß °¡Àå ÈçÇÑ ÇüÅÂÀÌ´Ù. º´¸®Á¶Á÷ÇÐÀûÀ¸·Î´Â ³úÀÇ Àü¹ÝÀûÀÎ À§Ãà, ³ú½ÇÀÇ È®Àå, ½Å°æ¼¶À¯ÀÇ ´Ù¹ß¼º º´ÅÍ(½Å°æ¼¶À¯µÚƲ¸²)¿Í ³ëÀιÝ(neuritic plaque) µîÀÌ Æ¯Â¡ÀÌ´Ù. ÀÓ»óÀûÀΠƯ¡Àº Á¡ÁøÀûÀÎ ±â¾ï-ÆÇ´Ü-¾ð¾î´É·Â µî ÁöÀûÀÎ ±â´ÉÀÇ °¨Åð¿Í ÀÏ»ó»ýȰ´É·Â-ÀΰÝ-Çൿ¾ç»óÀÇ Àå¾ÖÀÌ´Ù. º´¿¡ °É¸®¸é Ãʱ⿡´Â À̸§-³¯Â¥-Àå¼Ò¿Í °°Àº °ÍµéÀÌ ±â¾ï¿¡¼ »ç¶óÁö°í, ½ÉÇØÁö¸é ÈÀå½ÇÀ» °¡°Å³ª ¿ä¸®¸¦ Çϰųª ½ÅÀ» ½Å´Â ÀÏ µîÀÇ ÀÏ»ó»ýȰÁ¶Â÷µµ ÀØ°Ô µÈ´Ù. µ¿½Ã¿¡ ¿ì¿ïÁõ¼¼³ª ÀΰÝÀÇ È²Æó, °ÝÇÑ Çൿ µîÀÇ Á¤½ÅÀÇÇÐÀûÀÎ Áõ¼¼µµ µ¿¹ÝµÈ´Ù. ÀÌ·¯ÇÑ Áõ¼¼µéÀÌ Á¡ÀüÀûÀ¸·Î ÁøÇàµÇ¾î °á±¹Àº Á×À½¿¡ À̸£°Ô µÈ´Ù. ¹ßº´ ÈÄ ¼¼È÷ Á×À½¿¡ À̸£´Â ±â°£Àº 6~8³â Á¤µµÀÌÁö¸¸ »ç¶÷¿¡ µû¶ó 20³âÀÌ ³Ñ´Â °æ¿ìµµ ÀÖ´Ù. |
||
| ¿µ¹® | Addison disease | ÇÑ±Û | ¾Öµð½¼º´ |
|---|---|---|---|
| ¼³¸í | ºÎ½Å°ÑÁúÀÇ º´ÅÍ·Î ÀÎÇÏ¿© ºÎ½Å°ÑÁúÀÇ È£¸£¸óÀÌ ³ª¿ÀÁö ¸øÇؼ »ý±â´Â º´. ¿ì¸®³ª¶ó¿¡¼ °¡Àå ¸¹Àº ¿øÀÎÀº °áÇÙÀÌ´Ù. ¾Öµð½¼º´¿¡¼´Â ºÎ½Å°ÑÁúÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ ºÎ½Å°ÑÁú¿¡¼ ³ª¿À´Â È£¸£¸óÀÌ ¾ø¾îÁö¹Ç·Î ÄáÆÏ¿¡¼ ¹°ÀÇ Èí¼öÀå¾Ö·Î ÀÎÇØ Å»¼ö»óŰ¡ Áö¼ÓµÇ¸ç, ½ºÆ®·¹½º È£¸£¸óÀÇ °áÇÌ¿¡ ÀÇÇØ¼ ¸¸¼ºÇÇ·Î, üÁß°¨¼Ò µîÀÇ Áõ»óÀÌ »ý±â¸ç, ³úÇϼöü¿¡¼ ºÎ½Å°ÑÁúÀÇ ºÐºñ¸¦ ³ôÀÌ´Â ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸óÀÇ °ú´Ù ºÐºñ·Î ÀÎÇØ¼ °°ÀÌ ºÐºñµÇ´Â ¸á¶ó´ÑÀÚ±ØÈ£¸£¸ó¿¡ ÀÇÇØ ¾ó±¼°ú ÀÔ¼ú¿¡ °úµµÇÑ »ö¼ÒÀÇ Ä§ÂøÀ» º¼ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | inflammatory bowel disease | ÇÑ±Û | ¿°Áõ¼ºÃ¢ÀÚº´ |
|---|---|---|---|
| ¼³¸í | À§Àå°üÀ» ħ¹üÇÏ´Â Á¤È®ÇÑ ¿øÀÎÀÌ ¹àÇôÁöÁö ¾ÊÀº ¸¸¼ºÀûÀÎ ¿°Áõ¼º ÁúȯÀ» ¸»ÇÑ´Ù. Å©°Ô ¡®±Ë¾ç¼º ´ëÀå¿°¡¯(ulcerative colitis)°ú ¡®Å©·Ðº´¡¯(Crohn's disease)ÀÇ µÎ Á¾·ù·Î ±¸ºÐµÈ´Ù. ¹éÀÎ, À¯ÅÂÀο¡ ¸¹°í ÈæÀÎÀ̳ª µ¿¾çÀο¡´Â µå¹°Áö¸¸ µ¿¾çÀο¡¼ Á¡Â÷ Áõ°¡Ãß¼¼¿¡ ÀÖ´Ù. È£¹ß¿¬·ÉÀº 15~35¼¼ »çÀÌÀÌ´Ù. Áõ»óÀº ¡®±Ë¾ç¼º ´ëÀå¿°¡¯ÀÇ °æ¿ì, ¼³»ç(Ç÷º¯ ¹× Á¡¾×º¯), µÚ¹«Á÷, º¹Åë, º¹ºÎ¾ÐÅë, üÁß°¨¼Ò µîÀÌ ÁÖ·Î ³ªÅ¸³ª¸ç ¡®Å©·Ðº´¡¯¿¡¼´Â ¼³»ç¿Í üÁß°¨¼Ò, ¿ìÇϺ¹ºÎ Á¾·ù, Ç×¹®ÁÖÀ§ ÀÌ»ó, º¹ºÎ¾ÐÅë µîÀÌ ³ªÅ¸³´Ù. Áø´ÜÀº º´·Â°ú ¹æ»ç¼±ÇÐÀû °Ë»ç, Á÷Àå°æ ¹× ´ëÀå ³»½Ã°æ°Ë»ç, Á÷Àå ¹× ´ëÀåÀÇ Á¶Á÷°Ë»ç·Î Çϸç Ä¡·á´Â ³»°úÀûÀÎ Ä¡·á°¡ ¿øÄ¢À̳ª ³»°úÀû Ä¡·á¿¡ µèÁö ¾Ê°Å³ª ÇÕº´ÁõÀÌ »ý±æ °æ¿ì¿¡´Â ¿Ü°úÀû Ä¡·á¸¦ ½ÃÇàÇÑ´Ù. ¡®±Ë¾ç¼º ´ëÀå¿°¡¯ÀÇ °æ¿ì¿¡´Â ¡®´ëÀå¾Ï¡¯À» ¿¹¹æÇϱâ À§Çؼ ¿Ü°úÀû Ä¡·á¸¦ Çϱ⵵ ÇÑ´Ù. ¡®±Ë¾ç¼º ´ëÀå¿°¡¯°ú ¡®Å©·Ð º´¡¯¿Ü¿¡ ¿°Áõ¼º âÀÚº´¿¡ ¼ÓÇÏ´Â ¡®º£Ã¼Æ® º´¡¯Àº Àç¹ß¼º ±¸°³» ±Ë¾ç, ÇǺΠº´º¯, ¾È±¸ºÎ ¿°Áõ, ¿ÜÀ½ºÎ ±Ë¾ç, °üÀý¿° Áõ»ó, À§Ã¢ÀÚ°ü Áõ»ó(º¹Åë, ÀåÃâÇ÷), ºÎ°íȯ¿° µîÀÇ Áõ»óÀ» ³ªÅ¸³»´Âµ¥ Áø´Ü°ú Ä¡·á´Â ¡®±Ë¾ç¼º ´ëÀå¿°¡¯, ¡®Å©·Ð º´¡¯°ú ºñ½ÁÇÏ´Ù. |
||
| RD | radial deviation; radiology department; rate difference; Raynaud disease; reaction of degeneration; ... |
|---|---|
| ALL | Acute Lymphocytic Leukemia ÇüÅÂÇÐÀû ºÐ·ù L1; Small, Homogenous(... |
| CHD | Chediak-Higashi disease; childhood disease; chronic hemodialysis; congenital or congestive heart dis... |
| CRD | carbohydrate-recognition domain; chronic renal disease; chronic respiratory disease; child restraint... |
| NF | Neuro-Fibromatosis = Von Recklinghausen's Disease NF 1; Neuro-Fibroma... |
| optical storage devices | A computer disk read by a laser beam, containing data prerecorded by a vendor. The buyer cannot enter or modify data in any way but the advantages lie in the speed of accessibility, relative immunity to damage, and relatively low cost of purchase. (12 Dec 1998) |
|---|---|
| lead storage battery | <chemistry> A battery (used in cars) in which the anode is lead, the cathode is lead coated with lead dioxide, and the electrolyte is a sulfuric acid solution. (09 Jan 1998) |
| lipid storage diseases | A series of disorders due to inborn errors in lipid metabolism resulting in the abnormal accumulation of lipids in the wrong places (examples include gaucher, fabry and niemann-pick diseases and metachromatic leukodystrophy). (12 Dec 1998) |
| lysosomal storage diseases | Inborn errors of metabolism characterised by defects in specific lysosomal hydrolases and resulting in intracellular accumulation of unmetabolised substrates. (12 Dec 1998) |
| gaucher's disease, type 1 | A progressive genetic disease caused by a defect in an enzyme. The enzyme, called glucocerebrosidase, is needed to break down the chemical glucocerebroside. The enzyme defect in persons with Gaucher's disease (GD) leads to the accumulation of glucocerebroside in the spleen, liver, and lymph nodes. The most common early sign is enlargement of the spleen (located in the upper left abdomen). Other signs include low red blood cell counts (anaemia), a decrease in blood clotting cells (platelets), increased pigmentation of the skin, and a yellow fatty spot on the white of the eye (a pinguecula). Severe bone involvement can lead to pain and collapse of the bone of the hips, shoulders, and spine. The GD gene is on chromosome 1. The disease is a recessive trait. Both parents carry a GD gene and transmit it for their child with the disease. The parents' risk of a child with the disease is 1 in 4 with each pregnancy. This type of Gaucher's disease (noncerebral juvenile Gaucher's disease) is most common in Ashkenazi Jews (of European origin) and is the most common genetic disease among Jews in the United States. (12 Dec 1998) |
| Recklinghausen's disease type I | type 2 neurofibromatosis |
| central Recklinghausen's disease type II | type 1 neurofibromatosis |
| disease, gaucher's type 1 | A progressive genetic disease caused by a defect in an enzyme. The enzyme, called glucocerebrosidase, is needed to break down the chemical glucocerebroside. The enzyme defect in persons with Gaucher's disease (GD) leads to the accumulation of glucocerebroside in the spleen, liver, and lymph nodes. The most common early sign is enlargement of the spleen (located in the upper left abdomen). Other signs include low red blood cell counts (anaemia), a decrease in blood clotting cells (platelets), increased pigmentation of the skin, and a yellow fatty spot on the white of the eye (a pinguecula). Severe bone involvement can lead to pain and collapse of the bone of the hips, shoulders, and spine. The GD gene is on chromosome 1. The disease is a recessive trait. Both parents carry a GD gene and transmit it for their child with the disease. The parents' risk of a child with the disease is 1 in 4 with each pregnancy. This type of Gaucher's disease (noncerebral juvenile Gaucher's disease) is most common in Ashkenazi Jews (of European origin) and is the most common genetic disease among Jews in the United States. (12 Dec 1998) |
| angiotensin III | <chemical> A heptapeptide formed by the enzymatic hydrolysis of angiotensin II. It has greater activity than angiotensin II for stimulating aldosterone synthesis and in the release of prostaglandins but only 20% of the pressor activity. Chemical name: Angiotensin II, 1-de-L-aspartic acid- (12 Dec 1998) |
| annexin III | <enzyme> A protein of the annexin family that catalyses the conversion of 1-d-inositol 1,2-cyclic phosphate and water to 1-d-myo-inositol 1-phosphate. Chemical name: 1-D-myo-Inositol-1,2-cyclic-phosphate 2-inositolphosphohydrolase Registry number: EC 3.1.4.36 (12 Dec 1998) |
| antithrombin III | <haematology> Antithrombin III is a protein which stimulates the removal of blood clots in the bloodstream. Small blood clots form normally within the bloodstream, but are normally dissolved via the bodys antithrombin III. Conditions that may have an associated low value of antithrombin III include: liver disease and DIC. Normal values are: 0.20 to 0.45 mg/ml or more than 50% of the laboratory control value. Conditions where there is a deficiency of this important protease inhibitor can result in a condition of hypercoagulation, resulting in an increased risk for blood clot formation. Inheritance: autosomal dominant. (13 Jan 1998) |
| apolipoprotein C-III | <biochemistry> An apolipoprotein found in VLDL, HDL, and chylomicrons. (05 Mar 2000) |
| arsenazo III | <chemical> Metallochrome indicator that changes colour when complexed to the calcium ion under physiological conditions. It is used to measure local calcium ion concentrations in vivo. Pharmacological action: dyes, indicators and reagents. Chemical name: 2,7-Naphthalenedisulfonic acid, 3,6-bis((2-arsonophenyl)azo)-4,5-dihydroxy- (12 Dec 1998) |
| arteriae intercostales posteriores III-XI | posterior intercostal arteries 3-11 |
| band III protein | <protein> A 90 kD protein embedded in the surface of the human erythrocyte membrane, identified as the major anion transport/exchange protein. When the red blood cell is in the lungs, brings chlorine ion into the cell in exchange for bicarbonate. Analogous proteins exist in other erythrocytes. A dimeric transmembrane glycoprotein, with binding sites for many cytolasmic proteins, including ankyrin, on its cytoplasmic domain. (18 Nov 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|